Israel’s Can-Fite BioPharma has reported successful pre-clinical trials of CF101 for the treatment of anterior uveitis – the inflammation of the iris. An earlier trial found CF101 effective in treating posterior uveitis – inflammation of the retina. Uveitis is a common cause of blindness in the USA.
http://www.globes.co.il/serveen/globes/docview.asp?did=1000740443&fid=1725